FMC is focused on executing 2026 operational priorities including strengthening the balance sheet by paying down $1 billion in debt through asset sales and licensing agreements. Sales of new active ingredients are expected to be between $300 million and $400 million in 2026, representing growth of over 75 percent at the midpoint versus prior year.
Cyborg Score Rationale
FMC continues to operate in a difficult agricultural downcycle with overcapacity of agricultural chemicals and low margins for growers, while the company's chemical portfolio has largely gone off-patent, forcing price reductions. The company carries $4.07 billion in debt with a 5.8 times debt-to-EBITDA ratio.
Top Insights
Strategic review underway with potential sale authorization, driven by sharp stock decline (68-88% from peaks)
New active ingredients pipeline targeting $2B revenue by 2035, representing long-term optionality
Rynaxypyr patent expiration causing pricing pressure with 6% decline in Q4 2025; legacy portfolio facing competitive headwinds
India commercial business divestiture planned as part of $1B debt reduction initiative; high leverage ratios constrain flexibility
Named Competitors
Integrated Crop Solutions — Diversified agribusiness with seed and chemical platforms
Crop Protection — Global chemical producer with large agricultural division
Crop Protection Portfolio — China-backed global agrochemical leader
Recent Developments
(February 2026) Board authorized exploration of strategic options including potential company sale; 2026 guidance reduced
(Q4 2025) Revenue declined 12% YoY to $1.08B; GAAP loss of $1.72B driven by $1.36B goodwill impairment
(2025) Full-year revenue dropped 18% to $3.47B; new active ingredient sales reached ~$200M
Open the full interactive FMC Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.